Diagnostic value of PET/CT for predicting of neoadjuvant chemotherapy response.
Seemann
Marcus D
MD
Department of Radiology and Nuclear Medicine, University of Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany. marcus.seemann@medizin.uni-magdeburg.de
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods*; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D049268:Positron-Emission Tomography; D011379:Prognosis; D012272:Ribs / Q000473:pathology; D014057:Tomography, X-Ray Computed
D015251:Epirubicin; D003520:Cyclophosphamide